NVO Novo Nordisk A/S
$38.29▼ -0.98%
Healthcare
Other
Volume 11.35M
Avg Volume (10D) 9.12M
Key Metrics & Fundamentals
Market Cap
$168.89B
P/E Ratio
9.4
Div Yield
4.65%
52W Range
35.12 - 64.16
% vs 50 MA
-7.74%
% vs 200 MA
-13.74%
RSI-14
40.7
MACD Histogram
+0.2500
Beta (1Y vs SPY)
1.01
Free Cash Flow
$42.40B
Gross Rev
$78.49B
Gross Profit
$61.39B
EBITDA
$38.68B
COGS
$17.10B
Operating Exp
$34.33B
Operating Income
$27.06B
EBIT
$27.06B
Pretax Income
$26.88B
Net Income
$20.99B
EPS (Diluted)
4.74
Price & Volume History
Loading chart…
Recent News
Eli Lilly (LLY) Finds A New Lead In Diabetes As It Recasts Management
Simply Wall St. · Oct 28, 2026 7:15 PM ET
Novo Nordisk (CPSE:NOVO B) Stock Looks Cheap Even With Rival Pressure
Simply Wall St. · Oct 28, 2026 7:10 PM ET
Lilly's Reta Trounces Novo Powerhouse In Head-To-Head Test
Investor's Business Daily · Oct 28, 2026 4:12 PM ET
Sector Update: Healthcare Stocks Rise Late Afternoon
MT Newswires · Oct 28, 2026 3:51 PM ET
16% of Employers Are Thinking About Cutting Weight-Loss Drug Coverage
24/7 Wall St. · Oct 28, 2026 3:24 PM ET
Lilly’s retatrutide beats Ozempic in head-to-head trial
Clinical Trials Arena · Oct 28, 2026 2:23 PM ET
Sector Update: Healthcare Stocks Advance Wednesday Afternoon
MT Newswires · Oct 28, 2026 2:06 PM ET
Sector Update: Healthcare
MT Newswires · Oct 28, 2026 1:47 PM ET
Update: Eli Lilly Says Retatrutide Delivers Greater Weight Loss Than Ozempic in Adults With Type 2 Diabetes
MT Newswires · Oct 28, 2026 1:28 PM ET
Eli Lilly Says Retatrutide Delivers Greater Weight Loss Than Ozempic in Adults With Type 2 Diabetes
MT Newswires · Oct 28, 2026 10:29 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See NVO's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.